Risk adjusted net present value: What is the current valuation of Novartis’s XXB-750?

XXB-750 is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Systolic Heart Failure.

Related Posts

STAT+: Radiology captures the tension between AI’s pote...

Dec 1, 2023

Machine learning could help predict risk of preterm bir...

Sep 28, 2023

Listen: Lilly’s Alzheimer’s success, a milestone FDA ap...

May 5, 2023